These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25046202)

  • 41. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 43. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetic profiling joins personalized cancer medicine.
    Heyn H; Méndez-González J; Esteller M
    Expert Rev Mol Diagn; 2013 Jun; 13(5):473-9. PubMed ID: 23782254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of genomics on the path to personalized medicine.
    Tremblay J; Hamet P
    Metabolism; 2013 Jan; 62 Suppl 1():S2-5. PubMed ID: 23021037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next generation sequencing applications in cancer research.
    Zhang W; Nykter M; Chen K
    Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479
    [No Abstract]   [Full Text] [Related]  

  • 47. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
    Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
    Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
    Devarakonda S; Morgensztern D; Govindan R
    Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ethics and genomic medicine, how to navigate decisions in surgical oncology.
    Devon KM; Lerner-Ellis JP; Ganai S; Angelos P
    J Surg Oncol; 2015 Jan; 111(1):18-23. PubMed ID: 25183289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
    Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
    J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic alterations and personalized medicine in melanoma: progress and future prospects.
    Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
    Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
    BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy.
    Yang J; Du X
    Surg Oncol; 2013 Sep; 22(3):e53-7. PubMed ID: 23830351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.
    Cloonan N; Waddell N; Grimmond SM
    IDrugs; 2010 Nov; 13(11):778-81. PubMed ID: 21046525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy.
    Dutton-Regester K; Hayward NK
    Adv Pharmacol; 2012; 65():399-435. PubMed ID: 22959033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.
    van Rooij T; Marsh S
    Future Oncol; 2011 May; 7(5):649-56. PubMed ID: 21568680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.